Effect of ferric citrate for recovery from fatigue, phosphate binding, and iron supplementation in hemodialysis patients with well-controlled parathyroid hormone. -comparison with lanthanum carbonate-

Effect of ferric citrate for recovery from fatigue, phosphate binding, and iron supplementation in hemodialysis patients with well-controlled parathyroid hormone. -comparison with lanthanum carbonate- - Effect of ferric citrate for recovery from fatigue, phosphate binding capacity, and iron supplementation.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039788

Enrollment

Registered

2020-03-13

Start date

2020-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patients

Interventions

intervention: ferric citrate 1500 mg/day, 3 months control: lanthanum carbonate 1500 mg/day, 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Hemodialysis patients 2)TSAT < 20 % and serum ferritin < 100 ng/mL 3)Serum intact-PTH 60-240 pg/mL 4)Hb 9.0-11.5 g/dL 5)Serum phosphate >6.0 mg/dL or taking phosphate binders except for ferric citrate and Sucroferric oxyhydroxide.

Exclusion criteria

Exclusion criteria: 1)taking iron medication 2)malignancy, severe sepsis 3)gastrointestinal hemorrge 4)pregnant or possible pregnancy 5)Allergy to ferric citrate or lanthunum carbonate 6)Inappropriate patients regarded by doctor.

Design outcomes

Primary

Measure	Time frame
The ammount of fatigue score change in questionnaire consisted of 64 questions at 2weeks after administartion of ferric citrate or lanthum carbonate.	—

Countries

Japan

Contacts

Public ContactYu Tateishi

Ishikiri Seiki Hospital Department of Nephrology

y-tateishi@ishikiriseiki.or.jp072-988-3121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026